CompletedNCT03235908
Copeptin and Outcomes After Acute Psychosis, Including Bipolarity
About this title
Read the official source — NCT03235908Observational studyAges 18–55SwitzerlandSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- BaselSee all locations and recruitment
Study information
Study start dateStarted: May 1, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 73
- Sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- Hospital / academic medical center
- Study type
- Observational
- Intervention type
- OTHER
- Study phase
- Not clearly listed
- Locations
- Switzerland
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03235908
- Official title
Show the full official title
Copeptin - A Biomarker to Improve Outcome Prediction in Patients With an Acute Psychotic Episode
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Basel
Questions about this study
Who is behind this study?
The study sponsor is University Hospital, Basel, Switzerland, a hospital or academic medical center.
Who was this study for?
Listed age limits: 18 years to 55 years.
